

Dr. Ulrike Banning is working at IQVIA since 2014 and is a Senior Consultant of the European Thought Leadership Team. IQVIA is a multinational company serving the combined industries of health information technologies and clinical research. Its Thought Leadership Team provides an evidence-based viewpoint on key issues facing the pharmaceutical market – from identifying key trends that will shape the market to laying out specific implications and impact for pharmaceutical companies and other healthcare players. Ulrike Banning is focusing her work on Biologics/Biosimilars and market access trends. Before joining the Thought Leadership Team, she was working at the German Analytics & Local Consulting Team. In this role she supported the commercial effectiveness of IQVIA clients by primary market research and forecasting projects. Prior to this she was an Associate Editor for Clinical Medicine at the international scientific publishing company Springer Nature. She holds a PhD degree on Genetics from the German Cancer Research Center Heidelberg and a Master degree on Molecular Biology from the University of Mainz, Germany.